Source: International Congress 2017 – COPD management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Rhee (Seoul, Republic of Korea). Risk factors for discontinuation of roflumilast in COPD patients. 1060

Member's Comments

No comment yet.

Related content which might interest you: Risk factors for mortality in patients with COPD exacerbation Source: Annual Congress 2009 - Epidemiology of COPD Year: 2009 Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management Year: 2013 Risk factors of reintubation among patients with COPD Source: Eur Respir J 2007; 30: Suppl. 51, 313s Year: 2007 Effect of roflumilast on hospitalizations in COPD patients Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012 Risk factors for hospitalization of an acute exacerbation of COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 177s Year: 2006 Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial Source: International Congress 2018 – COPD management Year: 2018 Efficacy of PO moxifloxacin in the treatment of AECOPD in patients with risk factors for poor outcomes Source: Annual Congress 2009 - COPD case-finding and management in primary care Year: 2009 Risk factors of death in patients with COPD Source: Annual Congress 2009 - Prognosis and comorbidities in COPD Year: 2009 Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events: A population-based study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 Risk factors for severe exacerbations in asthma Source: Eur Respir J 2002; 20: Suppl. 38, 199s Year: 2002 Predicting factors for an exacerbation in patients with COPD during one year treatment with salmeterol/fluticasone or salmeterol Source: Eur Respir J 2004; 24: Suppl. 48, 512s Year: 2004 Risk factors of re-hospitalisation for a COPD exacerbation: a prospective study Source: Eur Respir J 2002; 20: Suppl. 38, 402s Year: 2002 Risk factors associated with hospitalized asthma patients Source: Eur Respir J 2001; 18: Suppl. 33, 51s Year: 2001 Key factors associated with readmission in COPD patients Source: Annual Congress 2013 –COPD biomarkers Year: 2013 Risk factors for another hospitalization in COPD patients hospitalized for exacerbation Source: International Congress 2016 – Hospitalisation and comorbidities in chronic lung diseases Year: 2016 QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study Source: International Congress 2014 – Asthma and COPD management Year: 2014 Cardiovascular medications and mortality in patients hospitalised with acute exacerbations of COPD Source: Annual Congress 2013 –COPD biomarkers Year: 2013 Risk factors of frequent exacerbations in difficult-to-treat asthma Source: Eur Respir J 2006; 27: 1324-1325 Year: 2006